Literature DB >> 16004665

Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes.

Philip Home1.   

Abstract

BACKGROUND: People with Type 2 diabetes mellitus are at high risk of cardiovascular disease and microvascular complications. A number of epidemiological studies have shown a strong relationship between the prevalence of vascular complications and raised levels of plasma glucose and glycated haemoglobin (HbA(1c)). Accumulating evidence supports the superior independent prognostic importance of the post-challenge glucose level, measured either 1 or 2 h after a glucose load. Thus, data from studies conducted in Europe, the USA, and particularly the Pacific rim and South Asia suggest that 2-h glucose is a better predictor of cardiovascular and all-cause mortality than pre-breakfast glucose, both in people with diabetes and those with pre-diabetic impaired glucose tolerance (IGT). Pathophysiological studies suggest that post-prandial rises in hyperglycaemia can trigger endothelial damage through multiple mechanisms, including increased oxidative stress and the increased expression of atherogenic circulating adhesion molecules and inflammatory cytokines that induce and regulate cell recruitment, migration, growth, and proliferation. Optimal pharmacological control of meal-time glucose levels can help to lower the HbA(1c) and thus may reduce the incidence of vascular complications in many people with diabetes. Moreover, emerging evidence suggests that reducing meal-time hyperglycaemia may delay the progression from pre-diabetic states toward overt diabetes. SCOPE: This review (based on MEDLINE searches, 1980-2005) examines the evidence linking the microvascular and macrovascular complications of diabetes and glycaemic control, assesses the relative contributions of basal and meal-time concentrations, and considers the implications for optimal treatment for people with Type 2 diabetes or with prediabetic IGT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16004665     DOI: 10.1185/030079905x49662

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  22 in total

1.  31P MR spectroscopy and in vitro markers of oxidative capacity in type 2 diabetes patients.

Authors:  S F E Praet; H M M De Feyter; R A M Jonkers; K Nicolay; C van Pul; H Kuipers; L J C van Loon; J J Prompers
Journal:  MAGMA       Date:  2006-12-19       Impact factor: 2.310

Review 2.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Dragana Lovre; Sulay Shah; Aanu Sihota; Vivian A Fonseca
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12-18       Impact factor: 4.741

3.  Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.

Authors:  Andreas Pfützner; Markolf Hanefeld; Lida A Dekordi; Jürgen Müller; Iris Kleine; Winfried Fuchs; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

4.  Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.

Authors:  Mark E Williams; Eduardo Lacson; Weiling Wang; J Michael Lazarus; Raymond Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

5.  The role of incretins in cardiovascular control.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

6.  Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?

Authors:  Chul Sik Kim; So Young Park; Sung Hoon Yu; Jun Goo Kang; Ohk Hyun Ryu; Seong Jin Lee; Eun Gyung Hong; Hyeon Kyu Kim; Doo-Man Kim; Jae Myung Yoo; Sung Hee Ihm; Moon Gi Choi; Hyung Joon Yoo
Journal:  Korean Diabetes J       Date:  2010-06-30

7.  Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes.

Authors:  Klaus Rave; Tim Heise; Lutz Heinemann; Anders H Boss
Journal:  J Diabetes Sci Technol       Date:  2008-03

8.  Altered disease course after initiation of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes (ROSSO 3).

Authors:  Hubert Kolb; Berthold Schneider; Lutz Heinemann; Volker Lodwig; Werner A Scherbaum; Stephan Martin
Journal:  J Diabetes Sci Technol       Date:  2007-07

9.  Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes.

Authors:  Cees J Tack; Vladimir Christov; Bastiaan E de Galan; Karl-Michael Derwahl; Gerhard Klausmann; Terezie Pelikánová; Jindra Perusicová; Anders H Boss; Nikhil Amin; David Kramer; Richard Petrucci; Wen Yu
Journal:  J Diabetes Sci Technol       Date:  2008-01

Review 10.  Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.